Is there any reason to believe that submitting another sample to you would provide any additional information or possible changes in treatment protocols now that we are almost 4 months into the treatment plan?

Is there any reason to believe that submitting another sample to you would provide any additional information or possible changes in treatment protocols now that we are almost 4 months into the treatment plan? Do you suggest additional test sampling as time goes on? Would it provide us with any additional information?

‍

Our Answer:

We would suggest you submit another FNA and blood samples to us WHEN the patient's lymphoma relapses. Relapse of lymphoma means that the cancer develops a resistance to certain chemo drugs in use. When this happens, the relapsed cancer cells are usually different from the ones investigated in the naive status, which led to different drug response predictions to the tested drugs. Therefore, it would be better to get new tumor samples and find out what are the new preferred drugs and which of the used drugs still remain effective or became resistant for the relapsed lymphoma. However, the best scenario is to maintain clinical remission for as long a period of time so that you don’t have to order another service from us! If a second service is needed, we offer a 50% discount for returning patients.

Can the testing be performed on dogs that are currently on therapy?

Current therapy will not affect our AI predictions or immunoprofile results. However, reduction of tumor size caused by therapy may increase the likelihood of service failure due to insufficient cells. In the event of service failure, you will not be billed.

What does the ImpriMed Personalized Prediction Profile include?

The Personalized Prediction Profile includes our Immunoprofile report and anticancer drug response predictions generated by artificial intelligence models. The predictions include estimates of both (1) the likelihood of a positive clinical response (partial response/ complete remission) to individual anticancer drugs and (2) the likelihood complete remission after 1 or 2 cycles of CHOP therapy, and the likelihood of early relapse after a successful CHOP regimen. Outcome predictions are currently provided for 13 individual drugs that are commonly used in many first-line and rescue protocols for the treatment of canine lymphoma (including CHOP, LOPP, MOPP, LPP, Tavonea only, etc…). Predictions are included for Doxorubicin, Cyclophosphamide, Vincristine, Vinblastine, Prednisone, Rabacfosadine (Tanovea®), L-Asparaginase, Lomustine, Mitoxantrone, Mechlorethamine, Dexamethasone, Chlorambucil, and Melphalan.

Can a doctor be associated with more than one hospital?

Yes, all account users can be associated with multiple hospitals. Please email support@imprimedicine.com if you want to add hospitals or clinics to your account.